vs

Side-by-side financial comparison of CME Group (CME) and Marvell Technology, Inc. (MRVL). Click either name above to swap in a different company.

Marvell Technology, Inc. is the larger business by last-quarter revenue ($2.1B vs $1.9B, roughly 1.1× CME Group). Marvell Technology, Inc. runs the higher net margin — 91.7% vs 0.1%, a 91.6% gap on every dollar of revenue. On growth, Marvell Technology, Inc. posted the faster year-over-year revenue change (36.8% vs 14.5%). Over the past eight quarters, Marvell Technology, Inc.'s revenue compounded faster (20.6% CAGR vs 10.8%).

CME Group Inc. is an American financial services company based in Chicago, Illinois. It operates financial derivatives exchanges, including the Chicago Mercantile Exchange (CME), the Chicago Board of Trade (CBOT), the New York Mercantile Exchange (NYMEX), and the Commodity Exchange (COMEX). The company owns 27% of S&P Dow Jones Indices. It is the world's largest operator of financial derivatives exchanges. Its exchanges are platforms for trading in agricultural products, currencies, energy, i...

Marvell Technology, Inc. is an American company, headquartered in Santa Clara, California, which develops and produces semiconductors and related technology. Founded in 1995, the company had more than 6,500 employees as of 2024, with over 10,000 patents worldwide, and an annual revenue of $5.5 billion for fiscal 2024.

CME vs MRVL — Head-to-Head

Bigger by revenue
MRVL
MRVL
1.1× larger
MRVL
$2.1B
$1.9B
CME
Growing faster (revenue YoY)
MRVL
MRVL
+22.4% gap
MRVL
36.8%
14.5%
CME
Higher net margin
MRVL
MRVL
91.6% more per $
MRVL
91.7%
0.1%
CME
Faster 2-yr revenue CAGR
MRVL
MRVL
Annualised
MRVL
20.6%
10.8%
CME

Income Statement — Q1 FY2026 vs Q3 FY2026

Metric
CME
CME
MRVL
MRVL
Revenue
$1.9B
$2.1B
Net Profit
$1.2M
$1.9B
Gross Margin
51.6%
Operating Margin
0.1%
17.2%
Net Margin
0.1%
91.7%
Revenue YoY
14.5%
36.8%
Net Profit YoY
20.7%
381.1%
EPS (diluted)
$2.20

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CME
CME
MRVL
MRVL
Q1 26
$1.9B
Q4 25
$1.6B
$2.1B
Q3 25
$1.5B
$2.0B
Q2 25
$1.7B
$1.9B
Q1 25
$1.6B
$1.8B
Q4 24
$1.5B
$1.5B
Q3 24
$1.6B
$1.3B
Q2 24
$1.5B
$1.2B
Net Profit
CME
CME
MRVL
MRVL
Q1 26
$1.2M
Q4 25
$1.2B
$1.9B
Q3 25
$908.0M
$194.8M
Q2 25
$1.0B
$177.9M
Q1 25
$956.2M
$200.2M
Q4 24
$874.6M
$-676.3M
Q3 24
$912.8M
$-193.3M
Q2 24
$883.2M
$-215.6M
Gross Margin
CME
CME
MRVL
MRVL
Q1 26
Q4 25
51.6%
Q3 25
50.4%
Q2 25
50.3%
Q1 25
50.5%
Q4 24
23.0%
Q3 24
46.2%
Q2 24
45.5%
Operating Margin
CME
CME
MRVL
MRVL
Q1 26
0.1%
Q4 25
61.8%
17.2%
Q3 25
63.3%
14.5%
Q2 25
66.7%
14.3%
Q1 25
67.5%
12.9%
Q4 24
62.1%
-46.4%
Q3 24
64.6%
-7.9%
Q2 24
65.3%
-13.1%
Net Margin
CME
CME
MRVL
MRVL
Q1 26
0.1%
Q4 25
71.7%
91.7%
Q3 25
59.1%
9.7%
Q2 25
60.6%
9.4%
Q1 25
58.2%
11.0%
Q4 24
57.3%
-44.6%
Q3 24
57.6%
-15.2%
Q2 24
57.6%
-18.6%
EPS (diluted)
CME
CME
MRVL
MRVL
Q1 26
Q4 25
$3.24
$2.20
Q3 25
$2.49
$0.22
Q2 25
$2.81
$0.20
Q1 25
$2.62
$0.23
Q4 24
$2.40
$-0.78
Q3 24
$2.50
$-0.22
Q2 24
$2.42
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CME
CME
MRVL
MRVL
Cash + ST InvestmentsLiquidity on hand
$2.4B
$2.7B
Total DebtLower is stronger
$3.4B
$4.5B
Stockholders' EquityBook value
$14.1B
Total Assets
$202.0B
$21.6B
Debt / EquityLower = less leverage
0.32×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CME
CME
MRVL
MRVL
Q1 26
$2.4B
Q4 25
$4.5B
$2.7B
Q3 25
$2.6B
$1.2B
Q2 25
$2.1B
$885.9M
Q1 25
$1.5B
$948.3M
Q4 24
$3.0B
$868.1M
Q3 24
$2.4B
$808.7M
Q2 24
$1.9B
$847.7M
Total Debt
CME
CME
MRVL
MRVL
Q1 26
$3.4B
Q4 25
$4.5B
Q3 25
$4.5B
Q2 25
$4.2B
Q1 25
$4.1B
Q4 24
$4.1B
Q3 24
$4.1B
Q2 24
$4.1B
Stockholders' Equity
CME
CME
MRVL
MRVL
Q1 26
Q4 25
$28.7B
$14.1B
Q3 25
$28.2B
$13.4B
Q2 25
$27.7B
$13.3B
Q1 25
$27.0B
$13.4B
Q4 24
$26.5B
$13.4B
Q3 24
$28.2B
$14.2B
Q2 24
$27.6B
$14.5B
Total Assets
CME
CME
MRVL
MRVL
Q1 26
$202.0B
Q4 25
$198.4B
$21.6B
Q3 25
$187.1B
$20.6B
Q2 25
$179.9B
$20.0B
Q1 25
$157.8B
$20.2B
Q4 24
$137.4B
$19.7B
Q3 24
$137.8B
$20.3B
Q2 24
$123.4B
$20.5B
Debt / Equity
CME
CME
MRVL
MRVL
Q1 26
Q4 25
0.32×
Q3 25
0.33×
Q2 25
0.32×
Q1 25
0.30×
Q4 24
0.31×
Q3 24
0.29×
Q2 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CME
CME
MRVL
MRVL
Operating Cash FlowLast quarter
$582.3M
Free Cash FlowOCF − Capex
$508.8M
FCF MarginFCF / Revenue
24.5%
Capex IntensityCapex / Revenue
3.5%
Cash ConversionOCF / Net Profit
0.31×
TTM Free Cash FlowTrailing 4 quarters
$1.6B

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CME
CME
MRVL
MRVL
Q1 26
Q4 25
$1.1B
$582.3M
Q3 25
$968.1M
$461.6M
Q2 25
$1.1B
$332.9M
Q1 25
$1.1B
$514.0M
Q4 24
$1.0B
$536.3M
Q3 24
$1.0B
$306.4M
Q2 24
$776.9M
$324.5M
Free Cash Flow
CME
CME
MRVL
MRVL
Q1 26
Q4 25
$1.1B
$508.8M
Q3 25
$949.7M
$414.1M
Q2 25
$1.0B
$214.1M
Q1 25
$1.1B
$444.1M
Q4 24
$991.7M
$461.3M
Q3 24
$973.2M
$258.2M
Q2 24
$758.7M
$233.0M
FCF Margin
CME
CME
MRVL
MRVL
Q1 26
Q4 25
66.8%
24.5%
Q3 25
61.8%
20.6%
Q2 25
61.5%
11.3%
Q1 25
67.1%
24.4%
Q4 24
65.0%
30.4%
Q3 24
61.4%
20.3%
Q2 24
49.5%
20.1%
Capex Intensity
CME
CME
MRVL
MRVL
Q1 26
Q4 25
2.0%
3.5%
Q3 25
1.2%
2.4%
Q2 25
1.1%
6.3%
Q1 25
0.9%
3.8%
Q4 24
1.7%
4.9%
Q3 24
1.9%
3.8%
Q2 24
1.2%
7.9%
Cash Conversion
CME
CME
MRVL
MRVL
Q1 26
Q4 25
0.96×
0.31×
Q3 25
1.07×
2.37×
Q2 25
1.03×
1.87×
Q1 25
1.17×
2.57×
Q4 24
1.16×
Q3 24
1.10×
Q2 24
0.88×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons